Pegylation of Poly(γ-benzyl-L-glutamate) Nanoparticles is Efficient for Avoiding Mononuclear Phagocyte System Capture in Rats

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2011 Jan 29

PMID 21270961

Citations 8

Authors

Ipek Ozcan

Freimar Segura-Sanchez

Kawthar Bouchemal

Murat Sezak

Ozgen Ozer

Tamer Guneri

Gilles Ponchel

Affiliations

Soon will be listed here.

Abstract

Poly(γ-benzyl-L-glutamate) (PBLG) derivatives are synthetic polypeptides for preparing nanoparticles with well controlled surface properties. The aim of this paper was to investigate the biodistribution of pegylated PBLG in rats. For this purpose, nanoparticles were prepared by a nanoprecipitation method using mixtures of different PBLG derivates, including a pegylated derivate to avoid mononuclear phagocyte system uptake. The morphology, size distribution, and surface charge of the nanoparticles were investigated as a function of the amount of polymer employed for the preparation. Moderately polydispersed nanoparticles (polydispersity index less than 0.2) were obtained. Their size increased with polymer concentration. The zeta potential values were negative whatever the formulations. The availability of polyethylene glycol chains on the nanoparticles' surface was confirmed by measuring the decrease in bovine serum albumin adsorption. For in vivo distribution studies, pegylated and nonpegylated nanoparticles were prepared with polymer mixtures containing PBLG-fluorescein isothiocyanate and imaged by fluorescence microscopy to measure their accumulation in liver and spleen tissues of rats after intravenous administration. Injection of stealth formulations resulted in negligible fluorescence in liver and spleen compared with nonpegylated formulations, which suggests that these nanoparticles are promising candidates as a stealth-type long-circulating drug carrier system and could be useful for active targeting of drugs while reducing systemic side effects.

Citing Articles

Tc Stearyl 6-(benzylidenehydrazinyl) nicotinamide Liposomes as Tumor Permeability Evaluation Tracer.

Cabrera M, Lecot N, Fernandez M, Gambini J, Porcal W, Cabral P AAPS PharmSciTech. 2021; 22(3):115.

PMID: 33763814 DOI: 10.1208/s12249-021-01984-1.

Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats.

Zakarial Ansar F, Latifah S, Wan Kamal W, Khong K, Ng Y, Foong J Int J Nanomedicine. 2020; 15:7703-7717.

PMID: 33116496 PMC: 7553255. DOI: 10.2147/IJN.S262395.

Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK.

Hu X, Rao S, Tan Y, Yin H, Luo M, Wang Z Theranostics. 2020; 10(17):7710-7729.

PMID: 32685015 PMC: 7359101. DOI: 10.7150/thno.45858.

Effect of Size and Concentration of PLGA-PEG Nanoparticles on Activation and Aggregation of Washed Human Platelets.

Bakhaidar R, Green J, Alfahad K, Samanani S, Moollan N, ONeill S Pharmaceutics. 2019; 11(10).

PMID: 31590303 PMC: 6835715. DOI: 10.3390/pharmaceutics11100514.

Engineering immunity in the mucosal niche against sexually transmitted infections.

Ramanathan R, Woodrow K Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015; 8(1):107-22.

PMID: 26153141 PMC: 6467227. DOI: 10.1002/wnan.1359.

References

Yang T, Cui F, Choi M, Cho J, Chung S, Shim C . Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007; 338(1-2):317-26. DOI: 10.1016/j.ijpharm.2007.02.011. View

Vila A, Gill H, McCallion O, Alonso M . Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J Control Release. 2004; 98(2):231-44. DOI: 10.1016/j.jconrel.2004.04.026. View

Redhead H, Davis S, Illum L . Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release. 2001; 70(3):353-63. DOI: 10.1016/s0168-3659(00)00367-9. View

Qi L, Xu Z . In vivo antitumor activity of chitosan nanoparticles. Bioorg Med Chem Lett. 2006; 16(16):4243-5. DOI: 10.1016/j.bmcl.2006.05.078. View

Sepassi S, Goodwin D, Drake A, Holland S, Leonard G, Martini L . Effect of polymer molecular weight on the production of drug nanoparticles. J Pharm Sci. 2007; 96(10):2655-66. DOI: 10.1002/jps.20979. View

Cheng J, Teply B, Sherifi I, Sung J, Luther G, Gu F . Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2006; 28(5):869-76. PMC: 2925222. DOI: 10.1016/j.biomaterials.2006.09.047. View

Kim T, Park T . Critical effect of freezing/freeze-drying on sustained release of FITC-dextran encapsulated within PLGA microspheres. Int J Pharm. 2004; 271(1-2):207-14. DOI: 10.1016/j.ijpharm.2003.11.021. View

Stolnik S, Heald C, Neal J, Garnett M, Davis S, Illum L . Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: production, colloidal properties and biological performance. J Drug Target. 2002; 9(5):361-78. DOI: 10.3109/10611860108998772. View

Govender T, Riley T, Ehtezazi T, Garnett M, Stolnik S, Illum L . Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm. 2000; 199(1):95-110. DOI: 10.1016/s0378-5173(00)00375-6. View

10.

Nanjwade B, Singh J, Parikh K, Manvi F . Preparation and evaluation of carboplatin biodegradable polymeric nanoparticles. Int J Pharm. 2009; 385(1-2):176-80. DOI: 10.1016/j.ijpharm.2009.10.030. View

11.

Zheng X, Kan B, Gou M, Fu S, Zhang J, Men K . Preparation of MPEG-PLA nanoparticle for honokiol delivery in vitro. Int J Pharm. 2009; 386(1-2):262-7. DOI: 10.1016/j.ijpharm.2009.11.014. View

12.

Mu L, Feng S . A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2002; 86(1):33-48. DOI: 10.1016/s0168-3659(02)00320-6. View

13.

Huang M, Gou M, Qian Z, Dai M, Li X, Cao M . One-step preparation of poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) nanoparticles for plasmid DNA delivery. J Biomed Mater Res A. 2007; 86(4):979-86. DOI: 10.1002/jbm.a.31704. View

14.

Bhadra D, Bhadra S, Jain P, Jain N . Pegnology: a review of PEG-ylated systems. Pharmazie. 2002; 57(1):5-29. View

15.

Gaumet M, Vargas A, Gurny R, Delie F . Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2007; 69(1):1-9. DOI: 10.1016/j.ejpb.2007.08.001. View

16.

Moghimi S, Szebeni J . Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003; 42(6):463-78. DOI: 10.1016/s0163-7827(03)00033-x. View

17.

Veronese F, Pasut G . PEGylation, successful approach to drug delivery. Drug Discov Today. 2005; 10(21):1451-8. DOI: 10.1016/S1359-6446(05)03575-0. View

18.

Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Livaniou E, Evangelatos G . Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int J Pharm. 2003; 259(1-2):115-27. DOI: 10.1016/s0378-5173(03)00224-2. View

19.

Wang D, Miller S, Sima M, Kopeckova P, Kopecek J . Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem. 2003; 14(5):853-9. DOI: 10.1021/bc034090j. View

20.

Zhu Z, Li Y, Li X, Li R, Jia Z, Liu B . Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release. 2009; 142(3):438-46. DOI: 10.1016/j.jconrel.2009.11.002. View